LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment

BACKGROUND: New predictors of the efficacy of hepatocellular carcinoma (HCC) immunotherapy are needed. The ability of a single gene mutation to predict the therapeutic effect of immune checkpoint inhibitors (ICI) in HCC remains unknown. METHODS: The most frequently mutated genes in HCC were analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yang, Tang, Rui, Li, Xiangzhao, Wang, Biao, Cheng, Yanling, Xiao, Shuzhe, Sun, Penghui, Yu, Wenxuan, Li, Cheng, Lin, Xinsheng, Zhu, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957351/
https://www.ncbi.nlm.nih.gov/pubmed/35345553
http://dx.doi.org/10.2147/JHC.S348785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957351/
https://www.ncbi.nlm.nih.gov/pubmed/35345553
http://dx.doi.org/10.2147/JHC.S348785

Ejemplares similares